复发性困难类杆菌感染:当前的临床管理和基于微生物组的治疗方法
1All India Institute of Medical Sciences, New Delhi, India.
概括
复发性Clostridioides difficile感染是一个主要问题. 标准化微生物群恢复疗法,如便微生物群移植和口腔子配方,为抗生素提供了有效的替代品,显著降低了复发率.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
背景情况:
- 困难菌感染 (CDI) 是医疗保健相关腹的主要原因.
- 高复发率 (主要后20-30%,三次发作后60%) 引发了严重的发病率和死亡率问题.
- 目前对复发性CDI的抗生素治疗有局限性.
研究的目的:
- 对复发性CDI的微生物组恢复疗法的疗效进行审查.
- 将这些疗法与传统的抗生素治疗和安慰剂进行比较.
- 突出便微生物群移植和基于微生物群的标准化疗法的优势和挑战.
主要方法:
- 对便微生物群移植 (FMT) 和标准化微生物群恢复疗法 (SMT) 的临床试验和研究的审查.
- 来自ECOSPOR III (SER-109) 和PUNCH CD3 (RBX2660) 等试验的复发率,疗效和安全数据的分析.
- 与传统抗生素疗法和安慰剂SMT的比较.
主要成果:
- 在复发性CDI中,FMT的成功率高于万科米辛,菲达克索米辛或安慰剂.
- 基于微生物组的标准化疗法SER-109和RBX2660显著降低了复发率 (分别为12%和40%和70.6%和57.5%).
- 这些药物现在已被FDA批准用于复发性CDI,其他药物正在开发中.
结论:
- 微生物组恢复疗法为治疗复发性CDI提供了抗生素的有希望的替代方案.
- 标准化方法克服了与传统FMT相关的异质性问题.
- 目前正在进行的研究探索疫苗,抗体疗法,以及用于治疗CDI的药物再利用.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
356
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
356
Inflammatory Bowel Disease V: Surgical Management
171
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
171
Microorganisms in Medicine and Therapeutics
58
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
58
Irritable Bowel Syndrome III: Medical and Nursing Management
244
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
244
Drugs for Treatment of Diarrhea-Predominant IBS
214
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
214


